cMYC inhibitor may hold promise for the management of tumors caused by MYB and MYBL1 translocations, Downstream MEK inhibitors are already in phase 2 in clinical trials for children with BRAF fused gliomas and phase 1 studies with FGFR1 inhibitors have started recently. This evidence concerns the gene MYB and central nervous system cancer.